key: cord-0714821-x5i48jgm
authors: Zhao, Tian-Shuo; Zeng, Hao-Long; Zhang, Xin; Chen, Xi; Jiang, Wan-Li; Du, Juan; Liu, Han-Yu; Zhao, Jing; Yuan, Yang; Peng, Xue-Fang; Li, Jia-Chen; Yang, Tong; Liu, Bao-Cheng; Li, Hui-Jun; Zhang, Xiao-Ai; Fang, Li-Qun; Lu, Qing-Bin; Cui, Fuqiang; Liu, Wei
title: Neurological manifestations in COVID-19 patients and their application in predicting fatal disease: a retrospective cohort study
date: 2021-08-25
journal: J Microbiol Immunol Infect
DOI: 10.1016/j.jmii.2021.07.010
sha: c79a061c5d8849713c629d9813f023a14ffb2cd4
doc_id: 714821
cord_uid: x5i48jgm

Background To explore the development of central nervous system (CNS) symptoms and clinical application in predicting the clinical outcome of SARS-COV-2 patients. Methods A retrospective cohort study was performed on the hospitalized patients with SARS-COV-2 recruited from four hospitals in Hubei Province, China from 18 January to 10 March 2020. The patients with CNS symptoms were determined. Data regarding clinical symptoms and laboratory tests were collected from medical records. Results Of 1268 patients studied, 162 (12.8%) had CNS symptoms, manifested as unconsciousness (71, 5.6%), coma (69, 5.4%), dysphoria (50, 3.9%), somnolence (34, 2.7%) and convulsion (3, 0.2%), which were observed at median of 14 (interquartile range 9-18) days after symptom onset and significantly associated with older age (OR=5.71, 95% confidence interval [CI] 2.78-11.73), male (OR=1.73, 95% CI 1.22-2.47) and preexisting hypertension (OR=1.78, 95% CI 1.23-2.57). The presence of CNS symptoms could be predicted by abnormal laboratory tests across various clinical stages, including by lymphocyte counts of <0.93×109/L, LDH≥435 U/L and IL-6≥28.83 pg/L at 0-10 days post disease; by lymphocyte count<0.86×109/L, IL-2R≥949 U/L, LDH≥382 U/L and WBC≥8.06×109/L at 11-20 days post disease. More patients with CNS symptoms developed fatal outcome compared with patients without CNS symptoms (HR=33.96, 95% CI 20.87-55.16). Conclusion Neurological symptoms of COVID-19 were related to increased odds of developing poor prognosis and even fatal infection.

The recent outbreak of COVID-19 caused by SARS-CoV-2 coronavirus has turned the 26 world into chaos with its ominously high rate of transmissions. Over 169 million cases of 27 confirmed COVID-19 have been reported worldwide 1 . Most patients manifest mild symptoms, 28 with most of the deaths occurring in patients over 60 years of age or those having underlying 29 diseases such as hypertension, diabetes and cardiovascular disease 2,3 . Although the predominant 30 clinical presentation is respiratory diseases, neurological manifestations that related to CoV-2 are increasingly recognized. At early epidemic, occasional development of neurological 32 signs and symptoms in COVID-19 patients, together with the isolation of SARS-CoV from the 33 brain of COVID-19 patient who had exhibited neurological features 4,5 , led to the postulation of 34 its neuropathy potential. Actually the expression and distribution of angiotensin converting 35 enzyme two (ACE2), the functional receptor for SARS-CoV-2, has been recently identified in 36 multiple human organs, including nervous system 6,7 , indicative of the capacity of SARS-CoV-37 2 in gaining access to the central nervous system (CNS) and causing neurological symptoms 38 through direct or indirect mechanisms. As the case incidence in the worldwide has increased, 39 there is more evidence showing the neurological complications caused by COVID-19 infection 40 from both retrospective case series or case reports, or even serve as the initial symptom of 41 COVID-19 8, 9 . The diagnosis of encephalitis was made from some case series 4,10,11 , and the 42 increased risk of cerebrovascular disease and necrotizing encephalopathy in association with 43 COVID-19 was replicated in other studies 12, 13 .

In the current study, we performed a retrospective study on COVID-19 patients in multiple 45 medical centers to explore the presence and outcome of CNS symptoms in 46 and to determine the role of commonly seen clinical features and laboratory findings involved Table 2 ). These symptoms appeared at median of 14 (IQR 9-18) days after symptom 104 onset, corresponding to around five days after hospital admission and last for three (IQR 1-8) 105 days ( Figure 1 ). When the symptoms were separately considered, somnolence was the earliest 106 one, presenting at 12 (IQR 6-18) days, and coma was the latest one presenting at 16 ( Inter-group comparison demonstrated that totally 28 abnormal findings were significantly 126 different, including 19 with elevated levels in patients with CNS vs. non-CNS symptoms, i.e., 127 lactic dehydrogenase (LDH), interleukin-6 (IL-6), fibrin degradation product (FDP), neutrophil 128 count, neutrophil percent, white blood cell (WBC), prothrombin time (PT), international 129 normalized ratio (INR), D-dimer, procalcitonin, C-reaction protein (CRP), IL-2R, lactic acid, 130 glucose, aspartate aminotransferase (AST), creatine kinase (CK), urea, CK-MB, and creatinine; 131 and 9 with decreased levels in patients with CNS symptoms, i.e., lymphocyte count, 132 lymphocyte percent, eosinophil count, eosinophil percent, platelet count, albumin, prealbumin, Table 4 ). Patients with CNS symptoms had lower lymphocyte percent 138 and counts, higher neutrophil percent and counts, abnormal liver function indicators of 139 decreased prealbumin and albumin, increased LDH and urea levels, as well as increased Table 4 ).

The discrimination of patients with CNS symptoms by applying multivariate analysis 148 Based on multivariate logistic regression model that were applied at the first stage, ten 149 indictors with AUC greater than 0.7 were entered the model, together with age, sex and 150 underlying comorbidities. The development of CNS symptoms was significantly associated 151 with clinical presence of rapid pulse, dyspnea, anhelation, anorexia, as well as lymphocyte 152 counts of <0.93×10 9 /L, LDH≥435 U/L and IL-6≥28.83 pg/L (Table 2 and Appendix Table   153 5). For the second stage, the development of CNS symptoms was significantly associated with 154 clinical presence of rapid pulse, cough, dyspnea, as well as lymphocyte count<0.86×10 9 /L, IL-155 2R ≥ 949 U/L, LDH ≥ 382 U/L and WBC ≥ 8.06×10 9 /L. For both stages, older age and 156 preexisting hypertension conferred higher risk of CNS symptoms development. (Figure 3 and Appendix Table 6 ). These associations were verified by survival 168 analysis showing that the CNS symptom as a whole, as well as each CNS symptom, were 169 significantly related to the increased risk of fatal outcome (Appendix Table 7 ).

The discrimination of fatal patients with CNS symptoms 171 We made further analysis within the patients with CNS symptoms to identify the clinical and 172 laboratory features that can be used to predict the development of fatal outcome (Table 3 thrombin time) and liver injury (increased LDH). All these abnormal evaluations indicated 191 organ injury, which could be used as predictors referring to patients with severe cases. The 192 exploring of significant predictors has allowed a differential diagnosis of cases at early stage 193 before the neurological manifestation before the advanced stage, which could be reasonably 194 lifesaving.

As has been increasingly studied, the neurological signs and symptoms observed in the 

In this study, male had a higher risk of CNS symptoms and death than women, consistent with 217 findings from gender-disaggregated data showing higher mortality rate in men 25 . Genetic 218 susceptibility caused by sex may be due to the differences in ACE2 and TMPRSS2 regulation 219 and mosaic advantage activated by X-heterozygous 26 . The bisexual differences in lifestyle, 220 comorbidities and treatment might also play roles 25, 27 . Notably, we observed presence of lip 221 cyanosis as a protective factor for death in this study. It's hypothesized that this apparent analysis. Except for CNS symptoms or diseases, we made no attempts to investigate the 237 peripheral nervous system (PNS) symptoms (hypogeusia, hyposmia, hyposmia, and neuralgia).

In conclusion, in agreement with the known capacity of SARS-CoV-2 in afflicting nervous 239 system, and related to increased odds of developing poor prognosis and even fatal infection.

The CNS symptoms mostly occurred at around two weeks after disease onset, and can predict 241 fatal outcome. It's accordingly suggested that a low threshold for imaging and CSF analysis in J o u r n a l P r e -p r o o f 

CI, confidence interval; LDH, lactic dehydrogenase; IL, interleukin; WBC, white blood cell